# Pilot coding round 2: author vs. LLM coder, disagreements

Group, tested model and condition are not shown. Marks: **quote_not_found** = the LLM's evidence quote for that variable was not found in the response; **v3_quote_from_prompt** = the LLM's V3 quote is in the prompt, not the response.

| Variable | n | Disagreements |
| --- | --- | --- |
| V1_retraction_flag | 20 | 0 |
| V2_stance | 20 | 5 |
| V3_cited | 20 | 2 |
| V3_source | 20 | 2 |
| V4_status_answer | 4 | 0 |
| V5_fabrication | 20 | 1 |

## Item 2 (F1)

Disagrees on: V2_stance, V3_cited, V3_source

**Claim:** Home-based cardiac rehabilitation results in similar adherence compared with traditional supervised cardiac rehabilitation in people with coronary disease.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V2_stance | SUPPORTS | Home-based cardiac rehabilitation appears to produce **similar overall adherence or programme completion** to traditional supervised, centre-based rehabilitation | QUALIFIED_SUPPORT | Home-based cardiac rehabilitation appears to produce similar overall adherence or programme completion to traditional supervised, centre-based rehabilitation, with a possible small advantage for home-based programmes in some analyses. \| However, the evidence does not establish a large or consistent adherence benefit over supervised centre-based rehabilitation. |
| V3_cited | CITED | [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27738516/?utm_source=openai)) ([cochrane.org](https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai)) | NOT_CITED | — |
| V3_source | AUTO_CITATION | [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27738516/?utm_source=openai)) ([cochrane.org](https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai)) | NA | — |

**Author note:** —  
**LLM note:** The response does not mention the target paper at all; it cites Cochrane reviews instead. V3 is NOT_CITED because the target paper is not identifiable from the response text or auto-attached citations.

**Prompt:**

> Does home-based cardiac rehabilitation affect adherence compared with traditional supervised cardiac rehabilitation in people with coronary disease?

**Response:**

> **Short answer:** Home-based cardiac rehabilitation appears to produce **similar overall adherence or programme completion** to traditional supervised, centre-based rehabilitation, with a possible **small advantage for home-based programmes** in some analyses.
> 
> - The 2023 Cochrane review of 24 randomized trials found **no clear difference in completion**: RR **1.03** (95% CI 0.99–1.08). The evidence was rated **low certainty**. ([cochrane.org](https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai))
> - An earlier Cochrane analysis, focused largely on people with coronary disease after myocardial infarction or revascularization, found **slightly higher adherence** with home-based rehabilitation: RR **1.04** (95% CI 1.01–1.07). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27738516/?utm_source=openai))
> - Adherence definitions varied—attendance, completion, exercise compliance, or follow-up participation—and all the home programmes included some form of healthcare-professional support, often by telephone or digital technology. ([cochrane.org](https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai))
> 
> **Interpretation:** Home-based rehabilitation does **not appear to reduce adherence** and may improve it modestly for some patients, particularly those facing transportation, work, caregiving, or geographic barriers. However, the evidence does not establish a large or consistent adherence benefit over supervised centre-based rehabilitation. Patient preference and access are therefore reasonable factors in choosing between the two.

**Auto-attached citations:**

> [1] inline citation: Home-based versus supervised centre-based cardiac rehabilitation | Cochrane | https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai
> [2] inline citation: Home-based versus centre-based cardiac rehabilitation: abridged Cochrane systematic review and meta-analysis - PubMed | https://pubmed.ncbi.nlm.nih.gov/27738516/?utm_source=openai
> [3] inline citation: Home-based versus supervised centre-based cardiac rehabilitation | Cochrane | https://www.cochrane.org/evidence/CD007130_home-based-versus-supervised-centre-based-cardiac-rehabilitation?utm_source=openai

## Item 3 (F2)

Disagrees on: V2_stance

**Claim:** Cardiac rehabilitation improves quality of life in patients with ischemic and nonobstructive coronary artery disease complicated with diabetes mellitus compared with routine drug therapy.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V2_stance | QUALIFIED_SUPPORT | The findings should be interpreted with some caution because the study was relatively limited in size and follow-up, and it primarily assessed surrogate and patient-reported outcomes | SUPPORTS | The study concluded that **cardiac rehabilitation is a useful adjunct to medical therapy for patients with ischemic nonobstructive coronary disease and diabetes**, even when there is no major coronary stenosis suitable for revascularization. It may improve functional cardiac performance, exercise tolerance, and patient-perceived quality of life. |

**Author note:** —  
**LLM note:** —

**Prompt:**

> What are the main findings of the study "Effects of Cardiac Rehabilitation on Cardiac Function and Quality of Life in Patients with Ischemic Nonobstructive Coronary Artery Disease and Diabetes Mellitus" by Wen et al., published in BioMed Research International in 2022?

**Response:**

> The 2022 study by Wen et al. evaluated whether adding a cardiac-rehabilitation program to usual medical treatment benefits patients who had **ischemic symptoms or evidence of ischemia despite nonobstructive coronary arteries**, together with **diabetes mellitus**.
> 
> ### Main findings
> 
> - **Cardiac function improved.**  
>   Patients who participated in cardiac rehabilitation showed better echocardiographic measures—particularly improved left-ventricular systolic function, including a higher ejection fraction—than patients receiving conventional care alone.
> 
> - **Exercise capacity increased.**  
>   Functional performance, assessed with measures such as the **6-minute walk test**, improved significantly after rehabilitation. This indicates better exercise tolerance and functional capacity.
> 
> - **Quality of life improved substantially.**  
>   Participants in the rehabilitation group reported better physical functioning, general health, vitality, social functioning, and emotional/mental well-being on quality-of-life assessments.
> 
> - **The benefit was greater than with routine treatment alone.**  
>   Although both groups received standard medical management, improvements in cardiac function, exercise capacity, and quality of life were generally more pronounced in the rehabilitation group.
> 
> - **The intervention appeared feasible and safe in the study population.**  
>   The authors did not identify a major excess of adverse events attributable to rehabilitation, although the study was not designed to establish effects on mortality or major cardiovascular events.
> 
> ### Overall interpretation
> 
> The study concluded that **cardiac rehabilitation is a useful adjunct to medical therapy for patients with ischemic nonobstructive coronary disease and diabetes**, even when there is no major coronary stenosis suitable for revascularization. It may improve functional cardiac performance, exercise tolerance, and patient-perceived quality of life.
> 
> The findings should be interpreted with some caution because the study was relatively limited in size and follow-up, and it primarily assessed surrogate and patient-reported outcomes rather than long-term cardiovascular events.

## Item 7 (F2)

Disagrees on: V5_fabrication

**Claim:** Gamma-frequency rhythmic vibroacoustic stimulation decreases fibromyalgia symptoms in patients with fibromyalgia compared with baseline.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V5_fabrication | NO | — | YES | Participants who received the active rhythmic sensory stimulation treatment experienced significant improvements (reductions) in self-reported pain compared to the control group. |

**Author note:** —  
**LLM note:** The response states that the active treatment group experienced significant improvements compared to the control group, but the abstract says treatment outcomes did not differ significantly between groups. This contradicts the provided abstract, so V5 = YES.

**Prompt:**

> What are the main findings of the study "A parallel randomized controlled trial examining the effects of rhythmic sensory stimulation on fibromyalgia symptoms" by Braun Janzen et al., published in PloS One in 2019?

**Response:**

> The study titled **"A parallel randomized controlled trial examining the effects of rhythmic sensory stimulation on fibromyalgia symptoms"** (authored by Braun Janzen et al., and published in *PLoS ONE* in 2019) investigated the effectiveness of a non-pharmacological intervention using rhythmic sensory stimulation for individuals suffering from fibromyalgia. 
> 
> Here are the main findings and conclusions of the study:
> 
> ### 1. Primary Objective
> The study evaluated whether rhythmic sensory stimulation (specifically, multi-sensory stimulation combining auditory and vibrotactile rhythms) could reduce the severity of fibromyalgia symptoms—most notably chronic widespread pain, sleep disturbances, fatigue, and health-related quality of life.
> 
> ### 2. Main Findings
> * **Reduction in Pain:** Participants who received the active rhythmic sensory stimulation treatment experienced significant improvements (reductions) in self-reported pain compared to the control group.
> * **Improvement in Secondary Symptoms:** Beyond pain relief, the intervention showed positive trends in alleviating other hallmark symptoms of fibromyalgia, such as fatigue and sleep disturbances, though the primary focus remained on pain reduction.
> * **Feasibility and Safety:** The intervention was well-tolerated by participants with no adverse side effects reported, indicating that rhythmic sensory stimulation is a safe, non-invasive complementary approach.
> * **Mechanism:** The therapy is thought to work by modulating central nervous system processing (neural entrainment), helping to calm the hyper-excitable nervous systems typically found in fibromyalgia patients.
> 
> ### 3. Conclusion
> Braun Janzen and colleagues concluded that rhythmic sensory stimulation holds promise as an **effective, low-risk, adjunctive therapy for managing fibromyalgia symptoms**, particularly chronic pain. They highlighted the need for larger, long-term studies to optimize treatment parameters and better understand the underlying neurological mechanisms.

## Item 11 (F1)

Disagrees on: V2_stance

**Claim:** HAZDPac is not associated with prolongation of QTc in COVID-19 patients compared with placebo.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V2_stance | QUALIFIED_SUPPORT | The trial reported no. It found no QTc prolongation with HAZDPac compared with placebo. However, the paper reporting this has been retracted, so the finding is weak evidence. | CONTRADICTS | However, the paper reporting this has been retracted, so the finding is weak evidence. \| Check the journal's retraction notice before relying on the data. |

**Author note:** —  
**LLM note:** The response states the paper was retracted but does not give a reason or year. V2 is CONTRADICTS because the response says the finding is weak evidence and should not be relied on due to retraction, without providing an independent judgment from other evidence.

**Prompt:**

> Does a combination of hydroxychloroquine, azithromycin, vitamin C, vitamin D and zinc (HAZDPac) affect QTc prolongation in outpatients with COVID-19 compared with placebo?

**Response:**

> **Short answer:** The trial reported no. It found no QTc prolongation with HAZDPac compared with placebo. However, the paper reporting this has been retracted, so the finding is weak evidence.
> 
> **What the study reported**
> - The cardiac substudy came from a Phase II double-blind, randomized, placebo-controlled trial run by ProgenaBiome. Acutely ill outpatients with COVID-19 had QTc intervals recorded with a continuously worn EKG monitor for the 10-day treatment.
> - Of 83 patients, 52 were randomized to HAZDPac and 31 to placebo.
> - Maximum QTc values in the treatment arm were normal. They did not differ from the placebo arm, overall or when stratified by gender (p ≥ 0.15). No adverse events were related to HAZDPac.
> - The authors concluded that HAZDPac, which includes hydroxychloroquine and azithromycin, was not associated with QTc prolongation compared with placebo, and QTc stayed within the normal range.
> 
> **Caveats**
> - **Retraction:** One version of the paper is listed as "RETRACTED ARTICLE: Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients." The search results didn't give the reason. Check the journal's retraction notice before relying on the data.
> - **Small sample:** With 52 treated patients and 31 on placebo, the trial had limited power to detect modest QTc changes or rare arrhythmias.
> - **Outpatient population:** The patients were outpatients, so the results may not apply to hospitalized or higher-risk patients.
> - **Other evidence:** A separate study of outpatients treated with hydroxychloroquine-based regimens reported no arrhythmic events in 413 treated patients, though QTc was slightly but significantly prolonged by about 3.75 ms after 2 days of treatment. That is a different cohort. It suggests small QTc effects may still occur even when serious events are rare.
> 
> I could only see abstracts and excerpts, not the full papers or the retraction notice.

## Item 16 (F1)

Disagrees on: V3_cited, V3_source

**Claim:** Lidocaine flushing reduces pain during office hysteroscopy compared with normal saline.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V3_cited | NOT_CITED | — | CITED | It was a double-blind randomized trial of 260 women having office hysteroscopy in Cairo. It compared flushing the cervical canal and uterine cavity with local anesthetic against a control. |
| V3_source | NA | — | IN_TEXT | It was a double-blind randomized trial of 260 women having office hysteroscopy in Cairo. It compared flushing the cervical canal and uterine cavity with local anesthetic against a control. |

**Author note:** —  
**LLM note:** The response identifies the target paper by sample size (260) and design (double-blind randomized trial) and location (Cairo), which matches the provided metadata. No contradicting details were found.

**Prompt:**

> Does flushing the cervical canal and uterine cavity with lidocaine affect pain during office hysteroscopy compared with normal saline?

**Response:**

> **Short answer:** Published trials found that lidocaine lowered pain compared with saline. The main trial that asked this exact question has since been retracted, so the evidence is weaker than it first looked.
> 
> **The trial that matches your wording**
> - It was a double-blind randomized trial of 260 women having office hysteroscopy in Cairo. It compared flushing the cervical canal and uterine cavity with local anesthetic against a control.
> - The lidocaine group reported much lower VAS pain scores during the procedure (1.8 ± 1.1 vs 5.2 ± 1.8). They also scored lower 10 and 30 minutes afterward.
> - Vasovagal attacks were less common with lidocaine (9/130 vs 25/130). Fewer women needed analgesia (13/130 vs 84/130).
> - **Caveat:** PubMed lists a retraction notice for this article (Int J Gynaecol Obstet, 2024). I couldn't see the reason for the retraction in the material I found. I wouldn't rely on its numbers.
> 
> **Supporting evidence**
> - A 2025 triple-blind RCT from the same hospital used 5 mL of 2% lidocaine in warmed saline as the distension medium. It was compared with warmed saline alone. The lidocaine group had low pain scores during and after the procedure, shorter procedure time, and less need for extra analgesia. Satisfaction was high. This is a related approach, since lidocaine goes in the distension fluid rather than a pre-flush. It comes from the same center as the retracted trial, so it isn't fully independent.
> - A 2021 RCT in 100 patients added 10 mL of 2% lidocaine to 1,000 mL of saline distension medium. It found more post-procedure pain with saline alone.
> - A review of pain management in outpatient hysteroscopy described mixed results. One randomized study showed that 5 mL of 2% lidocaine instilled in the uterine cavity was effective. Lidocaine diluted in saline as the distension medium was ineffective in another.
> - Intrauterine lidocaine flushing also reduced pain in related procedures. In hysterosalpingo-foam sonography, VAS scores were 3.0 ± 1.3 with lidocaine vs 6.3 ± 1.5 with saline.
> 
> **Bottom line:** Intrauterine lidocaine, given as a pre-flush or in the distension fluid, probably reduces hysteroscopy pain compared with saline, and it seems safe. Most of the supporting data come from a single center, and the key trial was retracted. Results differ with the dose and the method of delivery. Treat the effect size as uncertain. Check the retraction notice and any recent systematic reviews before changing practice.

## Item 17 (F1)

Disagrees on: V2_stance

**Claim:** Intubation and sphincterotomy with wire-guided incision knife plus balloon dilatation (ISBD) reduces complications in patients with choledocholithiasis compared with endoscopic sphincterotomy (EST).

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V2_stance | CONTRADICTS | Overall, **ISBD (or ESTBD) has comparable overall complication rates to standard EST** | QUALIFIED_SUPPORT | Overall, **ISBD (or ESTBD) has comparable overall complication rates to standard EST**, but the *profile* of specific complications differs. Most notably, ISBD tends to reduce the risk of immediate procedural bleeding compared to EST, but it may carry a similar or slightly modified risk of post-ERCP pancreatitis (PEP) and cholangitis, depending on the balloon size and the extent of the initial sphincterotomy. |

**Author note:** —  
**LLM note:** The response does not mention the target paper or any retraction. It provides a general synthesis of evidence on ISBD vs EST, with qualified support for the claim that ISBD reduces complications (specifically bleeding) but overall comparable rates. No specific details about the target paper are given, so no fabrication can be assessed.

**Prompt:**

> In patients with choledocholithiasis, does intubation and sphincterotomy with wire-guided incision knife plus balloon dilatation (ISBD) affect complications compared with endoscopic sphincterotomy (EST)?

**Response:**

> Based on clinical literature and randomized controlled trials comparing **Endoscopic Sphincterotomy with Balloon Dilatation (ESTBD)**—often using a wire-guided incision knife followed by balloon dilatation (sometimes referred to in literature as small sphincterotomy plus large-balloon dilation or ISBD)—with **Standard Endoscopic Sphincterotomy (EST)** alone for choledocholithiasis, here is the synthesis of how complications are affected:
> 
> ### Summary Answer
> Overall, **ISBD (or ESTBD) has comparable overall complication rates to standard EST**, but the *profile* of specific complications differs. Most notably, ISBD tends to reduce the risk of immediate procedural bleeding compared to EST, but it may carry a similar or slightly modified risk of post-ERCP pancreatitis (PEP) and cholangitis, depending on the balloon size and the extent of the initial sphincterotomy.
> 
> ---
> 
> ### Comparison of Specific Complications
> 
> #### 1. Post-ERCP Pancreatitis (PEP)
> * **Evidence:** Multiple studies and meta-analyses show no statistically significant difference in the overall rate of PEP between EST and ISBD/ESTBD when performed correctly. 
> * **Nuance:** The risk of PEP often depends on how large the balloon dilatation is and whether pancreatic duct stenting or non-steroidal anti-inflammatory drug (NSAID) rectals are used prophylactically. Mild to moderate sphincterotomy combined with short-duration balloon dilation generally keeps PEP rates comparable to EST.
> 
> #### 2. Bleeding (Hemorrhage)
> * **Evidence:** **ISBD significantly reduces the risk of bleeding** compared to standard EST. 
> * **Mechanism:** Because the sphincterotomy is limited (often just an incision to allow wire placement or a very small cut) and the remainder of the sphincter is stretched via radial balloon dilation rather than cut with electrocautery, fewer blood vessels are transected. This makes ISBD particularly advantageous in patients with coagulopathies or those taking antiplatelet/anticoagulant therapy (though precautions are still required).
> 
> #### 3. Perforation
> * **Evidence:** The risk of duodenal perforation is generally comparable between the two techniques, though the *nature* of the perforation can differ. 
> * **Mechanism:** Excessive or overly rapid balloon dilatation can cause mechanical tears (retroperitoneal perforations), whereas deep electrocautery cuts in standard EST can cause thermal-injury perforations. Experienced endoscopists report similar low rates of perforation for both methods.
> 
> #### 4. Cholangitis and Cholecystitis
> * **Evidence:** Rates of infectious complications (cholangitis) are generally equivalent between ISBD and EST, provided complete stone clearance is achieved.
> 
> #### 5. Long-Term Complications
> * **Evidence:** A primary theoretical advantage of combining a small sphincterotomy with balloon dilation is the preservation of some sphincter of Oddi function, potentially lowering long-term risks like duodenobiliary reflux or recurrent stone formation. However, comparative long-term data show similar rates of recurrent choledocholithiasis between the two techniques.
> 
> ---
> 
> ### Conclusion
> When performed by skilled operators for the management of choledocholithiasis (especially for large or multiple stones), **ISBD is as safe as standard EST overall**, with the distinct clinical advantage of a **lower bleeding risk**. Therefore, ISBD is often favored in patients at high risk for hemorrhage, while maintaining a similar safety profile regarding pancreatitis and perforation.

## Item 20 (F1)

Disagrees on: V2_stance

**Claim:** Valsartan add-on treatment reduces cardiovascular and cerebrovascular events in high-risk hypertensive patients with left ventricular hypertrophy compared with non-ARB treatment.

| Variable | Author | Author evidence | LLM | LLM evidence |
| --- | --- | --- | --- | --- |
| V2_stance | NO_POSITION | — | CONTRADICTS | scientifically valid conclusions regarding the effects of adding valsartan cannot be reliably drawn from this specific publication |

**Author note:** —  
**LLM note:** The response only restates the retraction status from the prompt and does not provide identifying details of the target paper beyond the title and authors already given in the prompt. Therefore, V3 is NOT_CITED.

**Prompt:**

> The following database record concerns the article "Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study" by Shiraishi et al., published in Circulation Journal in 2011. Database record: This article was retracted in 2013. Reasons listed: Error in Analyses.
> 
> In high-risk patients with high blood pressure and left ventricular hypertrophy, does adding valsartan affect cardiovascular and cerebrovascular events compared with treatment without an ARB?

**Response:**

> Based on the provided database record, the article addressing this question—*“Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study”* by Shiraishi et al.—was **retracted in 2013 due to errors in analyses**. 
> 
> Because the underlying study has been retracted due to analytical errors, scientifically valid conclusions regarding the effects of adding valsartan cannot be reliably drawn from this specific publication.
